Needham, MA, March 26, 2009 / b3c newswire / - Cambridge Healthtech Institute’s Fifth Annual Biomarker World Congress will be held May 27-29, 2009 at the Loews Philadelphia Hotel, Philadelphia, Pennsylvania. The advance registration deadline for this event is April 10, 2009.
The signature event in Cambridge Healthtech Institute's Biomarker Series, The Biomarker World Congress 2009 (www.biomarkerworldcongress.com) is dedicated to all areas of biomarker research spanning the pharmaceutical and diagnostic pipeline. The meeting brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers-making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies. The Congress also offers a balance of scientific sessions covering the latest research and strategic presentations and brainstorming sessions for the decision makers. Now in its fifth year, the Biomarker World Congress is the leading annual meeting dedicated to biomarker research and implementation that consistently delivers a cutting-edge agenda, 500+ senior delegates, and a sold-out exhibit hall.
Who Should Attend: Researchers and Executives working in the following areas should plan on attending
- Molecular Diagnostics
- Assay Development
- Personalized Medicine
- Clinical Pharmacology
- Translational Medicine
- Safety Assessment
- Clinical Trials
- Biomarker Qualification
- Oncology Drugs & Diagnostics
Executive ThinkTank: Collaborations, Consortia, and Funding Opportunities in Biomarker Development
Short Course: Fit-for-Purpose Biomarker Assay Development & Validation
Workshop: Biomarkers for Cancer Drug Development
- John Allinson, FIBMS, Laboratory Director, Veeda Clinical Research
- Stewart Bates, Ph.D., Director, Stevenage Core Technologies Group, Discovery Technology Group, GlaxoSmithKline
- John C. Bloom, V.M.D., Ph.D., Executive Director, Diagnostic & Experimental Medicine, Eli Lilly & Co.
- Michael E. Burczynski, Ph.D., Associate Director, Biomarker Lab, Clinical Translational Medicine, Wyeth Pharmaceuticals
- C. Thomas Caskey, M.D., F.A.C.P., Director & Chief Executive Officer, The Brown Foundation Institute of Molecular Medicine and Genetics, The University of Texas, Health Science Center at Houston
- Maryellen de Mars, Ph.D., Director, Clinical Biomarkers, The Critical Path Institute
- Viswanath Devanarayan, Ph.D., Director, Statistics, Biomarker Research, Abbott Laboratories
- Nicholas C. Dracopoli, Ph.D., Vice President, Biomarkers, Centocor Research & Development, Johnson & Johnson
- Iman El-Hariry, M.D., Ph.D., Group Director, Oncology MDC, GlaxoSmithKline Research & Development
- Robert E. Epstein, M.D., M.S., Senior Vice President, Medical & Analytical Affairs; Chief Medical Officer, Medco Health Solutions, Inc.
- Giora Feuerstein, M.D., Assistant Vice President & Head, Discovery Translational Medicine, Wyeth Research
- Paul J. Fielder, Ph.D., Senior Director & Senior Scientist, Early Development Pharmacokinetics, Pharmacodynamic and Bioanalytical Sciences, Genentech, Inc.
- Mark Fidock, Ph.D., Head, Biochemical and Molecular BioMarkers, Experimental Biological Sciences, Pfizer Limited
- Dorothee Foernzler, Ph.D., Biomarker-Experimental Medicine Leader, F. Hoffmann-La Roche AG
- Alberto Gutierrez, Ph.D., Deputy Director, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD), U.S. Food and Drug Administration
- Yiwu He, Ph.D., Senior Program Officer, Global Health Discovery, Bill & Melinda Gates Foundation
- Phil Hewitt, Ph.D., Head, Molecular Toxicology, Institute of Toxicology, Merck KGaA
- Darren Hodgson, Ph.D., Biomics Advisor, Oncology Therapy Area, AstraZeneca
- Arthur L. Holden, Ph.D., Chairman and Chief Executive Officer, International Serious Adverse Event Consortium, Ltd. (SAEC)
- Martina Kaufmann, Ph.D., Biomarker Project Leader, Early Clinical Development Oncology, Novartis Pharma AG
- Geert Kolvenbag, M.D., Ph.D., Global Product Vice President, Oncology, AstraZeneca Pharmaceuticals, Inc.
- Chetan Lathia, Ph.D., Director, Global Clinical Pharmacology, Bayer Corp.
- Kwan Lee, Ph.D., Senior Director, Department of Biostatistics and Data Management, GlaxoSmithKline
- Francois Legay, Ph.D., Global Head, Marker Localization & Assays, Novartis Pharma AG
- Lawrence J. Lesko, Ph.D., F.C.P., Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
- Klaus Lindpaintner, M.D., M.P.H., Head, Medical Genomics & Vice President, Research, F. Hoffmann-La Roche AG
- Helen M. Moore, Ph.D., Director, Biospecimen Research Network, National Cancer Institute, National Institutes of Health
- Patrick Y. Mueller, Ph.D., Project Leader, Safety Assessment, Novartis Pharma AG
- Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen, Inc.
- Christoph Petry, Ph.D., Head, Molecular Research Germany, Siemens Healthcare Diagnostics Products GmbH
- Wendy Sanhai, Ph.D., Senior Scientific Advisor, Office of the Commissioner, U.S. Food and Drug Administration
- Yaping Shou, M.D., Ph.D., Director, Oncology Biomarkers and Imaging, Novartis Pharmaceuticals
- Brian B. Spear, Ph.D., Director, Scientific Affairs, Global Pharmaceutical Research and Development, Abbott Labs
- Linda C. Surh, M.D., Ph.D., FRCPC, Director, CEDD Global Regulatory Affairs, Neurosciences and Pharmacogenetics, GlaxoSmithKline, UK
- Ole Vesterqvist, Ph.D., Senior Director, Biomarker Lab & Outsourcing, Clinical Translational Medicine, Wyeth Research
- Xinkang Wang, Ph.D., Head, Imaging Biomarker Group, Discovery Translational Medicine, Wyeth Research
- Jeffrey Waring, Ph.D., Associate Research Fellow & Group Leader, Cellular & Molecular Toxicology, Abbott Labs
- David Wholley, Director, Biomarkers Consortium, Foundation for the National Institutes of Health
Hans Winkler, Ph.D., Senior Director & Global Head, Oncology Biomarkers, Pharmaceutical Research & Development, Johnson & Johnson
About Cambridge Healthtech Institute - www.healthtech.com
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Barnett Educational Services, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.
Related biology news :1
For more information please visit: www.biomarkerworldcongress.com
. Vitamin C lowers levels of inflammation biomarker considered predictor of heart disease2
. Biomarkers for identifying infant infections3
. Researchers seeking to identify Alzheimers risk focus on specific blood biomarker4
. Urologists identify 7 biomarkers that may help pinpoint prostate cancer recurrence5
. Scientists find potential protein biomarkers for growth hormone6
. Biomarker predicts malignancy potential of HG-PIN lesions in the prostate7
. Biomarkers allow doctors to match therapy to patient8
. Genetic Engineering & Biotechnology News reports on cancer biomarkers9
. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design10
. A search for biomarkers for early detection of colorectal cancer11
. 4,000-year-old coral beds among worlds oldest living things, prof says